HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications.

Autor: Lovato G; Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy., Ciriolo L; Department of Pharmacy, University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy., Perrucci M; Department of Pharmacy, University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy., Federici L; Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy., Ippoliti R; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 Coppito, Italy., Iacobelli S; MediaPharma s.r.l., Via Colle dell'Ara, Chieti 66100, Italy., Capone E; Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy., Locatelli M; Department of Pharmacy, University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy. Electronic address: marcello.locatelli@unich.it., Sala G; Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara 'G. d'Annunzio', Via dei Vestini 31, Chieti 66100, Italy.
Jazyk: angličtina
Zdroj: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2023 Oct 25; Vol. 235, pp. 115642. Date of Electronic Publication: 2023 Aug 12.
DOI: 10.1016/j.jpba.2023.115642
Abstrakt: The present study focuses on the development and validation of an HPLC-DAD methodology for the detection of a potent chemotherapeutic agent, Maytansinoid Ravtansine (DM4), and its metabolite, S-methyl-DM4 (S-Me-DM4), in plasma samples. Methodologically, after a simple protein precipitation with acetonitrile and after drying 1 mL of supernatant, the sample (suspended with N,N-Dimethylacetamide, DMA) was directly analyzed by HPLC under isocratic elution using a mobile phase comprising milliQ water and methanol (25:75, v:v), both acidified with 0.1 % v:v formic acid. Employing a flow rate of 1.0 mL/min and a reversed-phase GraceSmart RP18 column thermostated at 40 °C, we achieved complete resolution and separation of DM4 and S-Me-DM4 within 13 min. The optimized injection volume of 20 μL and the wavelength set at 254 nm were utilized for quantitative analyses. Rigorous validation has not only ensured its reliability and reproducibility but has also addressed potential limitations associated with methodological inconsistency. The limit of detection and quantification of the method were 0.025 and 0.06 μg/mL for both the analytes, respectively. The calibration curve showed a good linearity in the range 0.06-20 μg/mL. For both analytes, the intraday precision and trueness were 2.3-8.2 % and -1.1 to 3.1 %, respectively, while the interday values were 0.7-10.1 % and -10.4 to 7.5 %, respectively. The developed methodology enables the concurrent determination and quantification of free DM4 and its metabolite, free S-Me-DM4, making it a valuable tool for assessing the pharmacokinetics and pharmacodynamics of DM4-based therapies. In addition, the procedure was successfully applied to analyse the presence of free DM4 or its metabolite, free S-Me-DM4, in human plasma samples spiked with the 1959-sss/DM4 antibody-drug conjugate (ADC). The utilization of the herein validated methodology allowed to confirm the presence of these analytes, thereby providing insights into their potential release from the ADC structure.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: